Effects of (S)-ketamine on striatal dopamine: A [11C]raclopride PET study of a model psychosis in humans

Journal of Psychiatric Research

Volumn 34, Issue 1, 2000, Pages 35-43

  Vollenweider, Franz X ^a,b   Vontobel, Peter ^b   Øye, Ivar ^c   Hell, Daniel ^a   Leenders, Klaus L ^b  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

(S) ketamine; 11C raclopride; Dopamine; Dopamine D2 receptor; Glutamate; Human; NMDA receptor antagonist; Positron emission tomography (PET); Psychopathology; Schizophrenia; Striatum

Indexed keywords

DOPAMINE 2 RECEPTOR; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RACLOPRIDE;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG EFFECT; EUPHORIA; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOSIS; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; BINDING, COMPETITIVE; CAUDATE NUCLEUS; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; MALE; PSYCHOSES, SUBSTANCE-INDUCED; PUTAMEN; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, N-METHYL-D-ASPARTATE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033988526     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(99)00031-X     Document Type: Article

References (57)

1. Andersson J.L., Marcus M., Nomikos G.G., Svensson T.H. Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn-Schmiedebergs Archives of Pharmacology. 349:1994;236-243.
2. Anis N.A., Berry S.C., Burton N.R., Lodge D. The dissociative anesthetics, ketamine and phencyclidine selective reduce excitation of central mammalian neurons by N-methyl-D-aspartate. British Journal of Pharmacology. 79:1983;565-575.
3. Das AMDP-System. Manual zur Dokumentation psychiatrischer Befunde. 1981;Springer-Verlag, Berlin.
4. Breier A., Adler C.M., Weisenfeld N., Su T.P., Elman I., Picken L., Malhotra A.K., Pickar D. Effects of NMDA antagonism on striatal dopamine release in healthy subjects - application of a novel PET approach. Synapse. 29:1998;142-147.
5. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Amercican Journal of Psychiatry. 154:1997;805-811.
6. Carter C. Topographic distribution of possible glutamatergic pathways from the frontal cortex to the striatum and substantia nigra in rats. Neuropsychopharmacology. 21:1982;379-383.
7. Carter C.J., L'Heureux R., Scatton B. Differential control by N-methyl-D-aspartate and kainate of striatal dopamine release in vivo: a trans-striatal dialysis study. Journal of Neurochemistry. 51:1988;462-468.
8. Cleghorn J.M., Garnett E.S., Nahmias C., Firnau G., Brown G.M., Kaplan R., Szechtman H., Szechtman B. Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Research. 28:1989;119-133.
9. Deakin J.F.W., Slater P., Simpson M.D.C., Gilchrist A.C., Skan W.J., Royston M.C., Reynolds G.P., Cross A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. Journal of Neurochemistry. 52:1989;1781-1786.
10. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse. 13:1993;350-356.
11. Dittrich A. Ätiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände. 1996;VWB-Verlag für Wissenschaft und Bildung, Stuttgart.
12. Dittrich a. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 31:1998;80-84.
13. Domino E.F., Chodoff P., Corssen S. Pharmacological effects of Cl-581, a new dissociative anesthetic in man. Clinical Pharmacology & Therapeutics. 6:1965;279-291.
14. Ebmeier K.P., Lawrie S.M., Blackwood D.H., Johnstone E.C., Goodwin G.M. Hypofrontality revisited: a high resolution single photon emission computed tomography study in schizophrenia. Journal of Neurology, Neurosurgery and Psychiatry. 58:1995;452-456.
15. French E.D., Mura A., Wang T. MK-801, phencyclidine (PCP) and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse. 13:1993;108-116.
16. Gouzoulis-Mayfrank E., Habermeyer E., Hermle L., Steinmeyer A.M., Kunert H.J., Sass H. Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study. European Journal of Psychiatry. 13:1998;399-406.
17. Gouzoulis-Mayfrank E., Thelen B., Maier S., Habermeyer E., Spitzer M., Sass H. Modulation of semantic priming effects by psilocybin, MDE (ecstasy) and D-methamphetamine. Neurology, Psychiatry and Brain Research. 6:1998;19-28.
18. Gross G., Huber G., Klosterkötter J., Linz M. Bonn Scale for the Assessment of Basic Symptoms. 1987;Springer, Berlin.
19. Hertel P., Mathe J.M., Nomikos G.G., Iurlo M., Mathe A.A., Svensson T.H. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behavioural Brain Research. 72:1995;103-114.
20. Ishimaru M., Kurumaji A., Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biological Psychiatry. 35:1994;84-95.
21. Kim J.S., Kornhuber H.H., Schmid-Burke W., Holzmüller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neuroscience Letters. 20:1980;379-382.
22. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. Journal of Neural Transmission. 77:1989;231-236.
23. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.F., Delaney R., Bremner J.D., Heiniger R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonists, ketamine, in humans. Archives of General Psychiatry. 51:1994;199-214.
24. 11C]raclopride studies. Journal of Cerebral Blood Flow & Metabolism. 16:1996;42-52.
25. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage. 4:1996;153-158.
26. Laruelle M., Abi-Dargham A., van Dyck C.H., Rosenblatt W., Zea-Ponce Y., Zoghbi S.S., Baldwin R.M., Charney D.S., Hoffer P.B., Kung H.F., et al. SPECT imaging of striatal dopamine release after amphetamine challenge. Journal of Nuclear Medicine. 36:1995;1182-1190.
27. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug - Sernyl. Archives of Neurology and Psychiatry. 81:1959;363-369.
28. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150.
29. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307.
30. Mathe J.M., Nomikos G.G., Hildebrand B.E., Hertel P., Svensson T.H. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. European Journal of Pharmacology. 309:1996;1-11.
31. Mele A., Fontana D., Pert A. Alterations in striatal dopamine overflow during rotational behavior induced by amphetamine, phencyclidine and MK-801. Synapse. 26:1997;218-224.
32. 3H]glutamate-binding sites in rat brain. Journal of Neuroscience. 5:(11):1985;2909-2919.
33. Murase S., Grenhoff J., Chouvet G., Gonon F.G., Svensson T.H. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neuroscience Letters. 157:1993;53-56.
34. Murase S., Mathe J.M., Grenhoff J., Svensson T.H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. Journal of Neural Transmission - General Section. 91:1993;13-25.
35. Nishijima K., Kashiwa A., Hashimoto A., Iwama H., Umino A., Nishikawa T. Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis. Synapse. 22:1996;304-312.
36. Øye I., Hustveit O., Maurset A., Ratti Moberg E., Paulsen O., Skoglund L.A. The chiral forms of ketamine as probes for NMDA-receptor function in humans. Kameyama T., Nabeshima T., Domino E.F. NMDA receptor related agents: biochemistry, pharmacology and behavior. 1991;381-389 NPP Books, Ann.Arbor.
37. Øye I., Paulsen O., Maurset A. Effects of ketamine on sensory perception: Evidence for a role of N-methyl-D-Aspartate receptors. Journal of Pharmacology and Experimental Therapeutics. 260:1992;1209-1213.
38. Parellada E., Catafau A.M., Bernardo M., Lomeña F., González-Monclús E., Setoain J. Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: a resting and activation SPECT study. Psychiatry Research: Neuroimaging. 55:1994;131-139.
39. Sabri O., Erkwoh R., Schreckenberger M., Owega A., Sass H., Buell U. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet. 349:1997;1735-1739.
40. Schloesser R., Simkowitz P., Bartlett E.J., Wolkin A., Smith G.S., Dewey S.L., Brodie J.D. The study of neurotransmitter interactions using positron emission tomography and functional coupling. Clinical Neuropharmacology. 19:1996;371-389.
41. Schmidt C.J., Fadayel G.M. Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. Journal of Pharmacology and Experimental Therapeutics. 277:1996;1541-1549.
42. Sherman A.D., Hegwood T.S., Baruah S., Waziri R. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biological Psychiatry. 30:1991;1191-1198.
43. Simpson M.D.C., Slater P., Royston M.C., Deakin J.F.W. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Schizophrenia Research. 6:1992;41-48.
44. 11C-raclopride in normal human subjects. Neuropsychopharmacology. 18:1998;18-25.
45. Strous R.D., Javitt D.C. The N-methyl-D-aspartate receptor and schizophrenia. Israel Journal of Medical Sciences. 32:1996;275-281.
46. Svensson T.H., Mathe J.M., Andersson J.L., Nomikos G.G., Hildebrand B.E., Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism. Journal of Clinical Psychopharmacology. 15:1995;11S-18S.
47. Takahashi K., Yamashita H., Zhang X.Y., Nakamura S. Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Research Bulletin. 41:1996;363-367.
48. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. Journal of Neuroscience. 16:1996;373-379.
49. Volkow N.D., Fowler J.S., Wang G.J., Dewey S.L., Schlyer D., MacGregor R.L., Logan J., Alexoff D., Shea C., Hitzemann R., Angrist B., Wolf A. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. Journal of Nuclear Medicine. 34:1993;609-613.
50. Vollenweider F.X., Bär T., Hell D. Wirkung von Midazolam auf die Ketamin-induzierte Modellpsychose. Fortschritte der Neurologie und Psychiatrie. 2:1996;142.
51. Vollenweider F.X., Leenders K.L., Scharfetter C., Antonini A., Maguire P., Missimer J., Angst J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [F-18]-fluorodeoxyglocose (FDG). European Journal of Neuropsychopharmacology. 7:1997;9-24.
52. Vollenweider F.X., Antonini A., Leenders K.L., Øye I., Hell D., Angst J. Differential Psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers measured by FDG-PET. European Journal of Neuropsychopharmacology. 7:1997;25-38.
53. 11C]raclopride. Neuropsychopharmacology 1999;20:423-33.
54. Vollenweider F.X., Bächle D., Umbricht D., Geyer M., Hell D. Sertindole reduces S-ketamine induced attentional deficits in healthy volunteers. Biological Psychiatry. 45:1999;100.
55. Wedzony K., Klimek V., Golembiowska K. MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Research. 622:1993;325-329.
56. Wheeler D., Boutelle M.G., Fillenz M. The role of N-methyl-D-aspartate receptors in the regulation of physiologically released dopamine. Neuroscience. 65:1995;767-774.
57. Zhang J., Chiodo L.A., Freeman A.S. Effects of phencyclidine, MK-801 and 1,3-di(2-toly) guanidine on non-dopaminergic midbrain neurons. European Journal of Pharmacology. 230:1993;371-374.